Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
PR Newswire —
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)...